openPR Logo
Press release

Metastatic Melanoma Market Growth with Worldwide Industry Analysis to 2024

01-29-2018 11:20 AM CET | Health & Medicine

Press release from: Transparency Market Research

Metastatic Melanoma Market Growth with Worldwide Industry

A severe form of cancer, melanoma is commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, is the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to UV radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body, it becomes strenuous to treat it due to the availability of a restricted range of treatment options. The selection of treatment line or systemic drug therapy entirely depends on the stage of melanoma.

Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when melanoma penetrates the skin deeper to reach various parts of a body, predominantly the subcutaneous tissue layer under the skin, lungs, bones, liver, brain, and lymph nodes. In the most severe case of metastasis, the gastrointestinal tract, adrenal glands, spleen, and heart can also be affected. Currently, only a limited set of therapies are available to promisingly treat burgeoning cases of metastatic melanoma patients. The disease thus requires more efficient and effective treatment options.

Obtain Report Details @

The prevalence of skin cancer in rising since the past few years (American Academy of Dermatology), which prompts at the growing demand for treatment options. The global metastatic melanoma market is driven by proven diagnostics and therapeutics, and has positive prospects following the ongoing research findings to treat the disease and extend patients’ life span. Technological developments and improving sophistication in healthcare facilities worldwide is a major factor supporting the market growth. Government initiatives related to early diagnosis and treatment awareness are playing a key role in pushing the metastatic melanoma market. Growing penetration of premium drug products and emergence of effective immune-therapies are also boosting the market further.

Metastatic Melanoma Market Trends

A new class of therapies is currently trending in the metastatic melanoma market, including targeted chemotherapy, targeted immunotherapy, targeted MAP-kinase therapy, anti-angiogenesis, and vaccines. While these therapeutic options individually aim to prolong patient life and maximize benefit, clinical trials are persisting in order to discover their combined benefits. Moreover, several new drugs and therapies are being invented and introduced to the market. In the near future, metastatic melanoma market may witness significant innovations in therapeutics, with a strong possibility of discovering customized therapy options.

Download Report Brochure @

For the stage IV melanoma, the U.S. FDA had approved only two drugs, including Dacarbazine (DTIC) and high-dose interleukin-2 (IL-2). However, both of these drugs have a range of side effects, and record successful treatment only in a negligible patient population. The market clearly needs a more effective class of treatments targeted to extended patient life span, substantial tumor shrinkage, and improved overall survival rate.

The recently approved drugs - BMY’s Yervoy (Ipilimumab) and Zelboraf (Vemurafenib) have entered the market with a promising outcome. The antitumor effects associated with these drugs are also being explored by researchers. Drugs such as Ipilimumab, Imatinib, and PLX4032 can be used in combination with a suitable therapy may result in an effective treatment for metastatic melanoma. In addition to drugs, several vaccines are trialled as well. The market may witness a new force of promising therapeutics in the near future.

Metastatic Melanoma Market: Region-wise Analysis

As per the regional analysis, the global market for metastatic melanoma is more pronounced in North America - especially in the U.S., as melanoma is one of the top cancer types affecting cancer patients in the U.S. The treatment rate is relatively higher as well. Europe is also a significant market, owing to rapid premium drugs invasion and increasing treatment rate. Asia Pacific is gradually emerging as a sizeable market for metastatic melanoma diagnostics and therapeutics.

Some of the key players in the global metastatic melanoma market are Abbott Diagnostics, Roche, GlaxoSmithKline, Agilent Technologies, Novartis, Merck, Sanofi, Pfizer, and Bristol-Myer Squibb.

Pre-Book Full Report @<ype=S

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metastatic Melanoma Market Growth with Worldwide Industry Analysis to 2024 here

News-ID: 920082 • Views:

More Releases from Transparency Market Research

Personalized Packaging Market Expected to Reach US$ 56.7 Billion by 2031 with 5.1% CAGR Growth
Personalized Packaging Market Expected to Reach US$ 56.7 Billion by 2031 with 5. …
The global personalized packaging market is experiencing significant growth driven by consumer preferences for unique and customized packaging solutions. Personalized packaging offers brands the opportunity to create memorable and engaging experiences, strengthen brand loyalty, and differentiate their products in competitive markets. Valued at US$ 32.8 billion in 2022, the industry is estimated to grow at a compound annual growth rate (CAGR) of 5.1% from 2023 to 2031, reaching a valuation
Boil-in Bags Market Projected to Reach USD 812.4 Million by 2031 with 6.1% CAGR Growth
Boil-in Bags Market Projected to Reach USD 812.4 Million by 2031 with 6.1% CAGR …
The boil-in bags market is witnessing substantial growth driven by the convenience and efficiency they offer in food preparation and storage. Valued at US$ 424.3 million in 2022, this market is estimated to grow at a robust compound annual growth rate (CAGR) of 6.1% from 2023 to 2031, reaching a valuation of US$ 812.4 million by the end of 2031. Market Overview: Boil-in bags have gained popularity as a convenient solution for
Medical Tubing Packaging Market to Reach USD 11.1 Billion by 2031 with 6.2% CAGR Growth
Medical Tubing Packaging Market to Reach USD 11.1 Billion by 2031 with 6.2% CAGR …
The global medical tubing packaging market serves as a crucial component of the healthcare industry, ensuring the safe and sterile delivery of medical devices and equipment. Valued at US$ 5.7 billion in 2022, this market is expected to witness robust growth, with a projected compound annual growth rate (CAGR) of 6.2% from 2023 to 2031, reaching a valuation of US$ 11.1 billion by the end of 2031. Request Sample Copy of
Fragrance Packaging Market Poised to Surpass USD 4.1 Billion by 2031 with 3.8% CAGR Growth
Fragrance Packaging Market Poised to Surpass USD 4.1 Billion by 2031 with 3.8% C …
The global fragrance packaging market plays a pivotal role in the cosmetics and personal care industry, providing packaging solutions that not only protect fragrances but also serve as an essential component of branding and consumer experience. Valued at US$ 2.8 billion in 2022, the industry is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2031, exceeding US$ 4.1 billion by 2031. Request Sample Copy

All 5 Releases

More Releases for Metastatic

Metastatic Melanoma Cancer Diagnostics Market Analysis and Forecasts to 2031
Metastatic Melanoma Cancer Diagnostics Market 2022 The global Metastatic Melanoma Cancer Diagnostics Market is expected to grow on an impertinent note in the next 10 years. It could witness a CAGR of 8% and reach US$ 2.9 Bn by 2021 - 2031. Data processing through Big Data is on the anvil. Clinical software solutions are there to help out, taking the help of Big Data. Thus, data accumulation as well as
Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types
Global Metastatic Melanoma Treatment Market Growth 2020-2025
The recent COVID-19 report added by GLOBAL INFO RESEARCHgives a detailed account of the drivers and restraints in the global Metastatic Melanoma Treatmentmarket. The research report, title[Global and China Metastatic Melanoma Treatment Market 2020 by Company, Type and Application, Forecast to 2025] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the global Metastatic Melanoma Treatmentmarket and the current trends that are likely
Metastatic Prostate Cancer Therapeutic and Disease Pipeline Review H2
Summary “Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end
Metastatic Hormone Refractory Prostate Cancer Market Lucrative Technological bre …
Cancer is one of the most fatal and chronic disorders, in which, there is development of tumor due to uncontrolled growth of cells in particular part of the body. Cancer is highly hazardous disease, in which, the mortality rate is extremely high, due to highly invasive nature and prolonged duration of disease. Metastatic hormone refractory prostate cancer is the cancer of prostate glands. Prostate cancer is the most common form
Metastatic Liver Cancer - Pipeline Research and Markets Insight, 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Metastatic Liver Cancer - Pipeline Insight, 2017”. This report provides comprehensive insights of the ongoing therapeutic research and development across Metastatic Liver Cancer. Request For Sample Report@ The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Metastatic Liver Cancer by